<?xml version='1.0' encoding='utf-8'?>
<document id="22381334"><sentence text="In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist."><entity charOffset="101-114" id="DDI-PubMed.22381334.s1.e0" text="corticotropin" /></sentence><sentence text="The absorption, distribution, metabolism, and excretion (ADME) and the pharmacokinetic characteristics of BMS-562086 [pexacerfont; 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo(1,5-a)-1,3,5-triazin-4-amine (DPC-A69448)] were investigated in vitro and in animals to support its clinical development"><entity charOffset="131-239" id="DDI-PubMed.22381334.s2.e0" text="8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo(1,5-a)-1,3,5-triazin-4-amine" /></sentence><sentence text=" BMS-562086 was orally bioavailable in rats, dogs, and chimpanzees, with an absolute oral bioavailability of 40" /><sentence text="1, 58" /><sentence text="8, and 58" /><sentence text="5%, respectively" /><sentence text=" BMS-562086 was extensively metabolized in hepatocytes from all species and completely metabolized in rats" /><sentence text=" The primary biotransformation pathways found for BMS-562086 in both liver microsomal and hepatocyte preparations and in rats were similar" /><sentence text=" These included O-demethylation, hydroxylation at the N-alkyl side chain and N-dealkylation"><entity charOffset="54-61" id="DDI-PubMed.22381334.s9.e0" text="N-alkyl" /></sentence><sentence text=" Multiple cytochromes P450 including CYP3A4/5 were involved in the metabolic clearance of BMS-562086" /><sentence text=" Both renal and biliary excretion played a significant role in elimination of the metabolites of BMS-562086" /><sentence text=" The involvement of other metabolic enzymes in addition to CYP3A4/5 in elimination of BMS-562086 suggests a reduced potential for drug-drug interaction through modulation of CYP3A4/5" /><sentence text=" Chimpanzees proved to be a good animal model in predicting BMS-562086 human clearance" /><sentence text=" Virtual clinical trials performed with a population-based ADME simulator suggested that a minimal dose of 100 mg daily would provide sufficient drug exposure to achieve plasma concentrations above the projected human efficacious plasma concentration of BMS-562086 (&gt; 500 nM)"><entity charOffset="254-264" id="DDI-PubMed.22381334.s14.e0" text="BMS-562086" /></sentence><sentence text=" In summary, BMS-562086 exhibited favorable ADME and pharmacokinetic properties for further development" /><sentence text="" /></document>